The Lancet:接受依非韦伦治疗的艾滋病感染孕妇所生婴儿的小头畸形风险增加

2019-11-19 不详 MedSci原创

美国国立卫生研究院(National Institutes of Health)资助的一项研究显示,接受含有依非韦伦(efavirenz)药物治疗的艾滋病毒感染孕妇所生婴儿的头畸形或小头畸形患儿的几率是接受其他抗逆转录病毒药物治疗的2到2.5倍。与正常头大小的儿童相比,小头畸形的儿童发育迟缓的风险也更高。这项研究是由哈佛公共卫生学院的Paige L. Williams博士及其同事完成的,发表在《柳

美国国立卫生研究院(National Institutes of Health)资助的一项研究显示,接受含有依非韦伦(efavirenz)药物治疗的艾滋病毒感染孕妇所生婴儿的头畸形或小头畸形患儿的几率是接受其他抗逆转录病毒药物治疗的2到2.5倍。与正常头大小的儿童相比,小头畸形的儿童发育迟缓的风险也更高。这项研究是由哈佛公共卫生学院的Paige L. Williams博士及其同事完成的,发表在《柳叶刀》杂志上。

该研究对3000多名孕妇在怀孕期间接受HIV治疗的婴儿进行了随访。在这项较早的研究中,从6个月大到5到7岁之间定期测量了孩子的头围。

研究人员使用两种分类系统对儿童的头部发育进行排名。第一个分类系统将美国疾病控制与预防中心为3岁以下儿童制定的标准与Nellhaus Charts相结合,后者是针对3岁以上儿童的较旧标准集。对于第二分类系统,研究人员是从出生到18岁时都参考了Nellhaus Charts。

根据内尔豪斯(Nellhaus)标准,母亲使用含有依非韦伦药物所生孩子患小头畸形的可能性是母亲采用其他方法治疗儿童的两倍。根据Nellhaus-CDC的综合标准,子宫内暴露于依非韦伦的儿童患小头畸形的可能性约为2.5倍。

在子宫中暴露于依非韦伦的141名儿童中,有14名(9.9%)患有小头畸形,而2842名未接触依非韦伦的儿童中有142名(5%)。研究人员指出,暴露于所有其他类型的HIV治疗与小头畸形的高风险无关。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811083, encodeId=e14d18110838c, content=<a href='/topic/show?id=bf6b8680136' target=_blank style='color:#2F92EE;'>#艾滋病感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86801, encryptionId=bf6b8680136, topicName=艾滋病感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Oct 23 10:29:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928267, encodeId=70f9192826ee3, content=<a href='/topic/show?id=8d4d4e00124' target=_blank style='color:#2F92EE;'>#小头畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47001, encryptionId=8d4d4e00124, topicName=小头畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Dec 11 20:29:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830344, encodeId=1f9018303449e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 18 23:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362310, encodeId=ea49136231067, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Nov 21 10:29:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811083, encodeId=e14d18110838c, content=<a href='/topic/show?id=bf6b8680136' target=_blank style='color:#2F92EE;'>#艾滋病感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86801, encryptionId=bf6b8680136, topicName=艾滋病感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Oct 23 10:29:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928267, encodeId=70f9192826ee3, content=<a href='/topic/show?id=8d4d4e00124' target=_blank style='color:#2F92EE;'>#小头畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47001, encryptionId=8d4d4e00124, topicName=小头畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Dec 11 20:29:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830344, encodeId=1f9018303449e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 18 23:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362310, encodeId=ea49136231067, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Nov 21 10:29:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811083, encodeId=e14d18110838c, content=<a href='/topic/show?id=bf6b8680136' target=_blank style='color:#2F92EE;'>#艾滋病感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86801, encryptionId=bf6b8680136, topicName=艾滋病感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Oct 23 10:29:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928267, encodeId=70f9192826ee3, content=<a href='/topic/show?id=8d4d4e00124' target=_blank style='color:#2F92EE;'>#小头畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47001, encryptionId=8d4d4e00124, topicName=小头畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Dec 11 20:29:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830344, encodeId=1f9018303449e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 18 23:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362310, encodeId=ea49136231067, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Nov 21 10:29:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
    2020-03-18 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811083, encodeId=e14d18110838c, content=<a href='/topic/show?id=bf6b8680136' target=_blank style='color:#2F92EE;'>#艾滋病感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86801, encryptionId=bf6b8680136, topicName=艾滋病感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Oct 23 10:29:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928267, encodeId=70f9192826ee3, content=<a href='/topic/show?id=8d4d4e00124' target=_blank style='color:#2F92EE;'>#小头畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47001, encryptionId=8d4d4e00124, topicName=小头畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Dec 11 20:29:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830344, encodeId=1f9018303449e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 18 23:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362310, encodeId=ea49136231067, content=<a href='/topic/show?id=9857e03444b' target=_blank style='color:#2F92EE;'>#畸形#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70344, encryptionId=9857e03444b, topicName=畸形)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Thu Nov 21 10:29:00 CST 2019, time=2019-11-21, status=1, ipAttribution=)]
    2019-11-21 wushaoling

相关资讯

DCR: IPAA手术失败后修复重建的成功率与患者储袋功能的完整性十分相关

由于IPAA手术对慢性溃疡性结肠炎患者有着良好的治疗效果,IPAA的修复和重建手术很少见。所以对接受IPAA修复或重建的慢性溃疡性结肠炎患者的手术和功能的结果目前并没有很好的探索。本研究旨在确定接受IPAA修复或重建的慢性溃疡性结肠炎患者预后结局。

The Lancet:Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

AbbVie的口服JAK1选择性抑制剂upadacitinib治疗中度至严重活动性类风湿性关节炎的关键性III期SELECT-MONOTHERAPY临床试验的积极结果,发表在顶尖杂志"The Lancet"上。

欢迎参加The Oncologist “Immuno-Oncology In China”特刊发布会

诚邀您参加The Oncologist "Immuno-Oncology in China"特刊发布会或观看发布会直播。

诚邀您参加The Oncologist

诚邀您参加The Oncologist "Immuno-Oncology in China"特刊发布会或观看发布会直播。

Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法

Be The Match BioTherapies是一家为开发和商业化细胞和基因疗法的生物制药公司,Be The Match BioTherapies近日宣布,将与Kiadis Pharma合作,使造血干细胞移植(HSCT)疗法更安全、更有效。

J Gastroenterology:肿瘤部位对III期结肠癌淋巴结数量的影响与预后的关系

目前文献对结肠癌患者肠系膜淋巴结比(LNR)的预后意义的定义并不一致。本项研究的目的是确定右侧和左侧结肠癌中LNR的适当临界值,并阐明其临床意义。